Therapeutic thyroid hormone ligand patents 1998 – 2003

Bibliography

• RYONO DE, GROVER JG, MELLSTROM K: Chapter 12: Thyroid hormones and thyromimetics. In: BurgerS Medicinal Chemistry and Drug Discovery (6th Ed, Vol. 3). Abraham JA (Ed.), John Wiley & Sons (2003).
   Google Scholar
• LAZAR MA: Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr. Rev (1993) 14:184–193.
   PubMed Web of Science ®Google Scholar
• JOHANSSON C, VENNSTROM B, THOREN P: Evidence that decreased heart rate in thyroid hormone receptor-al-deficient mice is an intrinsic defect. Am. J. Physiol. (1998) 275:R640–R646.
   Google Scholar
• FORREST D, VENNSTROM B: Functions of thyroid hormone receptors in mice. Thyroid (2000) 10:41–52.
   PubMed Web of Science ®Google Scholar
• TAKEDA K, SAKURAI A, DEGROOT LJ, REFETOFF S: Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-I3 gene. I. Cl/n. Endocrin. (1992) 74:49–55.
   PubMed Web of Science ®Google Scholar
• WAGNER RL, APRILETTI JW, WC-RATH ME, WEST BL, BAXTER JD, FLETTERICK RJ: A structural role for hormone in the thyroid hormone receptor. Nature (1995) 378:690–697.
   PubMed Web of Science ®Google Scholar
• DARIMONT BD, WAGNER RL, APRILETTI JW et al.: Structure and specificity of nuclear receptor-coactivator interactions. Genes Devel. (1998) 12:3343–3356.
   PubMed Web of Science ®Google Scholar
• WAGNER RL, HUBER RB, SHIAU AKet al.: Hormone selectivity in thyroid hormone receptors. Mol. Endocrin. (2001) 15:398–410.
   Google Scholar
• DOW RL, SCHNEIDER SR, PAIGHT ES et al.: Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands. potent, TRB subtype-selective thyromimetics. Bioorg. Med. Chem. Lett. (2003) 13:379–382.
   PubMedGoogle Scholar
• YE L, LI Y-L, MELLSTROM K et al.: Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor Pk. Chem. (2003) 45:1580–1588.
   Google Scholar
• BECK-PECCOZ P, SARTORIO A, DE MEDICI C, GRUGNI G, MORABITO F, FAGLIA G: Dissociated thyromimetic effects of 3,5,3'-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels. J.Endocrin.Invest. (1988) 11:113–118.
   PubMedGoogle Scholar
• RENNER P, NOVARTIS PHARMA AG: Strategic planning, company communication (16 November 1999). (IDdb3 drug report: No. 347827).
   Google Scholar
• HARWOOD HI Jr, HAMANAKA ES: Modulators of dyslipidaemia. Emerg. Drugs (1998) 3:147–172.
   Google Scholar
• KARO BIO AB: Press release (31 August 2001). Iddb3 drug report: No. 420745.
   Google Scholar
• KARO BIO AB: Press release (27 March 2002). IDdb3 drug report: No. 480442.
   Google Scholar
• GROVER G, MELLSTROM K, YE L et al.: Selective thyroid hormone receptor-activation: a strategy for reduction of weight, cholesterol, and Lp(a) with reduced cardiovascular liability. Proc. Nati Acad. Sci. USA (2003) 100:10067–10072.
   PubMed Web of Science ®Google Scholar
• EBISAWA M, INOUE N, FUKASAWA H, SOTOME T, KAGECHIKA H: Thiazolidinediones with thyroid hormone receptor agonistic activity. Chem. Pharm. Bull. (1999) 47:1348–1350.
   PubMedGoogle Scholar
• CHIELLINI G, APRILETTI JW, YOSIHHARA HA, BAXTER JD, RIBEIRO RCJ, SCANLAN TS: A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem. Biol. (1998) 5:299–306.
   PubMed Web of Science ®Google Scholar
• TROST SU, SWANSON E, GLOSS B et al.: The thyroid hormone receptor-I3-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology (2000) 141:3057–3064.
   PubMed Web of Science ®Google Scholar
• BOWLER J, LILLEY TJ, PITTAM JD, WAKELINGG AE: Novel steroidal pure anti-estrogens. Steroids (1989) 54:71–91.
   PubMedGoogle Scholar
• WAKELING AE, BOWLER J: Steroidal pure antioestrogens. Endocrin. (1987) 112:R7–R10.
   Web of Science ®Google Scholar
• YOSIHAHARA HAI, APRILETTI JW, BAXTER JD, SCANLAN TS: A designed antagonist of the thyroid hormone receptor. Bioorg. Med. Chem. Lett. (2001) 11:2821–2825.
   PubMedGoogle Scholar
• BAXTER JD, GOEDE P, APRILLETTI JW et al.: Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology (2002) 143:517–524.
   PubMedGoogle Scholar
• CHIELLINI G, NGUYEN N-H, APRILETTI JW, BAXTER JD, SCANLAN TS: Synthesis and biological activity of novel thyroid hormone analogues: 50-aryl substituted GC-1 derivatives. Bioorg. Med. Chem. (2002) 10:333–346.
   PubMed Web of Science ®Google Scholar
• NGUYEN N-H, APRILETTI JW, LIMA ST, WEBB P, BAXTER JD, SCANLAN TS: Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. Med. Chem. (2002) 45:3310–3320.
   Google Scholar
• LIM W, NGUYEN N-H, YANG HY, SCANLAN TS, FURLOW JD: A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J. Biol. Chem. (2002) 277:35664–35670.
   PubMedGoogle Scholar
• BORNGRAEBER S, BUDNY MJ, CHIELLINI G et al.: Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Nati Acad. ScL USA (2003) 100:15358–15363.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA N, WALKER GN, MAIN AJ et al.: Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. J . Med. Chem. (1995) 38: 695–707.
   PubMed Web of Science ®Google Scholar
• STANTON JL, CAHILL E, DOTSON R et al.: Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to L-thyronine. Bioorg. Med. Chem. Lett. (2000) 10:1661–3.
   PubMedGoogle Scholar
• HANGELAND JJ, DEJNEKA T, FRIENDS TJ et al.: Thyromimetics with improved selectivity for the thyroid hormone receptor 13. The 226th ACS National Meeting, Division of Medidnal Chemistry New York, USA (2003) MEDI 321.
   Google Scholar
• RIBEIRO MO, CARCALHO SD, SCHULTZ JJ et al.: Thyroid hormonesymapthetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific. I Clin. Invest. (2001) 108:97–105.
   PubMedGoogle Scholar
• DE LANGE P, LANNI A, BENEDUCE L et al.: Uncoupling protein-3 is a molecular determinant for the regulation of resting metabolic rate by thyroid hormone. Endocrinology (2001) 142:3414–3420.
   PubMedGoogle Scholar
• MIRSKY IA, BROH-KNHA RH: Am. J. Physiol. (1936) 117:6.
   Google Scholar
• CASLA A, ROVIRA A, WELLS JA, DOHM GL: Increased glucose transporter (GLUT4) protein expression in hyperthyroidism. Biochem. Biophys. Res. Commun. (1990) 171:182–188.
   PubMed Web of Science ®Google Scholar
• RAMOS S, GOYA L, ALVAREZ C et al.:Different role of insulin in GLUT-1 and -4 regulation in heart and skeletal muscle during perinatal hypothyroidism. Am. J. Physiol. Endocrinol. Metab. (2001) 281:E1073–E1081.
   Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III): Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD AH, EMMETTH JC, ELLIS D et al.: A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature (1986) 324:425–9.
   PubMed Web of Science ®Google Scholar
• LEESON PD, EMMETTH JC, SHAH VPet al.: Selective thyromimetics. Cardiac-sparing thyroid hormone analogues containing 3'-arylmethyl substituents. J. Med. Chem. (1989) 32:320–336.
   Google Scholar
• RAKOW AD, KLOR HU, KUTER E, DITSCHUNEIT HH, KITSCHENEIT H: Treatment of Type II hyperlipoproteinemia with d-thyroxine. Atherosclerosis (1976) 24:369–380.
   PubMed Web of Science ®Google Scholar
• RIDGWAY ND, DOLPHIN PJ: Serum activity and hepatic secretion of lecithin cholesterol acyltransferase in experimental hypothyroidism and hypercholesterolemia. J. Lipid Res. (1985) 26:1300–1313.
   PubMedGoogle Scholar
• SCARABOTTOLO L, TREZZI E, ROMA P, CATAPAN AL: Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. Atherosclerosis (1986) 59:329–333.
   PubMedGoogle Scholar
• DE BRUIN TW, VAN BARLINGEN H, VAN LINDE-SIBENIUS TRIP M, VAN VUURST DE VRIES AR, AKVELD MJ, ERKELENS DW: Lipoprotein (a)and apolipoprotein B plasma concentrations in hypothyroid, euthryoid, and hyperthyroid subjects. I Clin. Endocrinol. Met. (1993) 76:121–126.
   PubMed Web of Science ®Google Scholar
• SINGH BN, VAUGHAN WILLIAMS EM: The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br. J. Pharmacol. (1970) 39:657–667.
   PubMed Web of Science ®Google Scholar
• LATHAM KR, SELETTI DF, GOLDSTEIN RE: The effects of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. J. Am. Coll. Cardiol. (1987)472–450.
   Google Scholar
• NORMAN ME LAVIN TA: Competition of thyroid hormone action by amiodarone in rat pituitary tumor cells. I Clin. Invest. (1989) 83:306–313.
   PubMedGoogle Scholar
• BOSCH RF, Li G-R, GASPO R, NATTEL S: Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes. Pharmacol. Exp. The]: (1999) 289:156–165.
   PubMedGoogle Scholar
• SINGH BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am. J. Cardiol. (1996) 78:41–53.
   PubMed Web of Science ®Google Scholar
• KODAMA I, KAMIYA K, TOYAMA J: Cellular electropharmacology of amiodarone. Cardiovasc. Res. (1997) 35:13–29.
   PubMed Web of Science ®Google Scholar
• DRVOTA V, CARLSSON B, HAEGGBLAD J, SYLVEN C: Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype pi, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect. Cardiovasc. Pharmacol. (1995) 26:222–226.
   PubMed Web of Science ®Google Scholar
• VAN BEEREN HC, BAKKER 0, WIERSINGA WM: Desethylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone al-receptor protein. Mol. Cell. Endocrin. (1995) 112:15–19.
   PubMedGoogle Scholar
• BAKKER 0, VAN BEEREN HC, WIERSINGA WM: Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone I31-receptor protein. Endocrinology (1994) 134: 1665-1670
   Google Scholar
• VAN BEEREN HC, JONG WM, KAPTEIN E, VISSER TJ, BAKKER 0, WIERSINGA WM: Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-at: M vitro and in vivo evidence. Endocrinology (2003) 144:552–558.
   PubMedGoogle Scholar
• CARLSSON B, SINGH BN, TEMCIUC Met al.: Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB-130015) with an improved toxicity profile comared with amiodarone. J. Med. Chem. (2002) 45:623–630.
   Google Scholar
• CHALMERS DK, MUNRO SLA, ISKANDER MN, CRAIK DJ: Models for the binding of amiodarone to the thyroid hormone receptor. I Comput. Aided MM. Des. (1992) 6:19–31.
   PubMedGoogle Scholar
• SHAHRARA S, DRVOTA V, SYLVEN C: Organ specific expression of thyroid hormone receptor mRNA and protein in different human tissues. Biol. Pharm. Bull. (1999) 22:1027–1033.
   PubMedGoogle Scholar
• BLANGE I, DRVOTA V, YEN PM, SYLVEN C: Species differences in cardiac thyroid hormone receptor isoforms protein abundance. Biol. Pharm. Bull. (1997) 20:1123–1126.
   PubMedGoogle Scholar
• KAASIK A, SEPPET EK, OHISALO JJ: Enhanced negative inotropic effect of an adenosine Al-receptor agonist in rat left atria in hypothyroidism. I. Ma Cell. Cardiol (1994) 26:509–517.
   PubMedGoogle Scholar
• EL-ANI D, JACOBSON KA, SHAINBERG A: Characterization of adenosine receptors in intact cultured heart cells. Biochem. Pharmacol (1994) 48:727–735.
   PubMedGoogle Scholar
• KLEIN I, OJAMAA K: Thyroid hormone and the cardiovascular system. N Engl. Med. (2001) 344:501–509.
   PubMed Web of Science ®Google Scholar
• HORSLEY V: The thyroid gland: its relation to the pathology of myxoedema and cretinism, to the question of surgical treatment of goitre, an to the general nutrition of the body. Br. Med. J. (1885) 1:111–115.
   PubMedGoogle Scholar
• REFETOFF S, MATALON R, BIGAZZI M: Metabolism of L-thyroxine (T4) and L-triiodothyronine (T3) by human fibroblasts in tissue culture: Evidence for cellular binding proteins and conversion of T4 to T3. Endocrinology (1972) 91:934–947.
   PubMedGoogle Scholar
• HUANG TS, CHOPRA IJ, BEREDO A, SOLOMON DH, CHUA TECO GN: Skin is an active site for the inner ring monodeiodination of thyroxine to 3,39,59-triiodothyronine. Endocrinology (1985) 117:2106–2113.
   PubMed Web of Science ®Google Scholar
• KAPLAN MM, PAN C, GORDON PR, LEE JK, GILCHREST BA: Human epidermal keratinocytes in culture convert thyroxine to 3,5,3'-triiodothyronine by Type II iodothyronine deiodination: A novel endocrine function of skin. J. Clin. Endocrinol Metab. (1988) 66:815–822.
   PubMedGoogle Scholar
• TORMA H, ROLLMAN 0, VAHLQUIST A: Detection of mRNA transcripts for retinoic acid, vitamin D3, and thyroid hormone (c-erb-A) nuclear receptors in human skin using reverse transcription and polymerase chain reaction. Acta Derm. Venereol (1993) 73:102–107.
   PubMed Web of Science ®Google Scholar
• BILLONI N, BUAN B, GAUTIER B, GAILLARD 0, MAHE YF, BERNHARD BA: Thyroid hormone receptor 131 is expressed in the human hair follicle. Br. J. Dermatol (2000) 142:645–652.
   PubMed Web of Science ®Google Scholar
• TORMA H, KARLSSON T, MICHAELSSON G, ROLLMAN 0, VAHLQUIST A: Decreased mRNA levels of retinoic acid receptor-a, retinoid X receptor-a and thyroid hormone receptor-a in lesional psoriatic skin. Acta Derm. Venereol (2000) 80:4–9.
   PubMed Web of Science ®Google Scholar
• SAFER JD, FRASER LM, RAYS, HOLICK MF: Topical triiodothyronine stimulates epidermal proliferation, dermal thickening, and hair growth in mice and rats. Thyroid (2001) 11:717–724.
   PubMed Web of Science ®Google Scholar
• FAERGEMANN J, SARNHULT T, HEDNER E et al.: Dose-response effects of tri-iodothyroacetic acid (TRIAC) and other thyroid hormone analogues on glucocorticoid induced skin atrophy in the haired mouse. Acta Derm. Venereol Scand. (2002) 82:179–183.
   PubMed Web of Science ®Google Scholar
• HOATH SB, LAKSHMANAN J, FISHER DA: Structure-activity relation of thyroid hormone analogues and tissue epidermal growth factor concentrations in neonatal and adult mice. Am. j Dis. Child (1984) 138:251–253.
   PubMedGoogle Scholar
• BAXTER JD, DILLMANN WH, WEST BL et al.: Selective modulation of thyroid hormone receptor action. J. Steroid Biochem. Ma Biol. (2001) 76:31.
   PubMed Web of Science ®Google Scholar